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Glia have been implicated in schizophrenia, although whether they play a primary role is 
uncertain. In this issue, Windrem et al. (2017) transplant human glial progenitors from 
schizophrenia patients into mouse brains, which develop abnormalities and behaviors 
characteristic of schizophrenia, thereby suggesting  glia’s primary role in the complex 
disease pathogenesis.  
Our understanding of the causes of schizophrenia, one of the most severe and widely 
occurring psychiatric disorders, has come a very long way from its characterization during 
most of the 20th century as a functional psychosis without an organic cause in terms of brain 
disorder. The biological basis of the disease in now beyond dispute, based on an ever 
increasing body of evidence from imaging, pathology and response to medication. However, 
at a cellular level, the mechanistic basis of the disease remains uncertain. In the study by 
Windrem and colleagues, the authors employ a highly imaginative stem-cell based approach 
to provide evidence for a primary role of glia, the non-neuronal cells of the CNS, in the 
aetiology of schizophrenia and in so doing, not only make a significant step forward in 
understanding the mechanistic basis of the disease, but also resolve a current ‘chicken-and-
egg’ debate within the field.  
 
The CNS comprises several types of cell. In addition to neurons, which, through their extensive 
network of processes and connections, establish the functional circuitry of the brain, there 
are two other major cell types - astrocytes and oligodendrocytes, the latter being the myelin-
forming cells of the CNS. Collectively the astrocytes and oligodendrocytes are called glia – a 
term coined by Rudolf Virchow in the 19th century to describe the non-neuronal cells of the 
CNS. The term glia, derived from the Greek for glue, reflects the mystery that originally 
surrounded these cells – in the absence of any more informed understanding they were 
regarded as the cells that ‘glued’ the apparently more important neurons together. The 
historical uncertainty about what glia did led to a neuron-centric view of the CNS and its 
diseases. It is not surprising therefore that one of the earlier and now best established 
biological models of the underlying mechanisms of schizophrenia was based on a primary 
dysfunction in dopamine neurons (the dopamine hypothesis) (Howes and Kapur, 2009). 
However, in recent years, a primary pathogenic role for glia has emerged in several diseases 
which ultimately manifest themselves as neuronal disorders including some of the classic 
neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS – or motor neuron 
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disease) and Huntington’s disease (Benraiss et al., 2016; Kang et al., 2013). There is even 
growing evidence for a role for glia in Alzheimer’s disease. These discoveries are entirely 
consistent with the emergent recognition of a central trophic role for both astrocytes and 
myelinating oligodendrocytes in maintaining neuronal (and axonal) health and integrity 
(Nave, 2010). If glia play key roles in these diseases, then why not in a highly complex 
psychiatric disorder such as schizophrenia? Several lines of evidence have emerged over the 
last few years to indicate that astrocytes and oligodendrocytes are perhaps not passive 
bystanders. First, imaging studies have revealed a paucity of white matter (the main 
myelinated part of the CNS) in schizophrenics (McIntosh et al., 2008). Second, pathological 
studies suggest that schizophrenics have abnormal myelin (Uranova et al., 2011). Third, 
genetic studies have highlighted significant changes in expression of both astrocyte and 
oligodendrocyte associated genes (Hakak et al., 2001). However intriguing these data, do they 
point to a primary role for glia in the disease? The difficulty is that all of these changes could 
potentially be explained as secondary to a primary neuronal problem. For example, since 
many neurons project their axons through regions of white matter, then it is inevitable that 
there will be white matter changes if something goes awry with the neurons. The white 
matter changes per se do not provide compelling evidence for a causal role for glia.  
 
To resolve the question of whether glia play a primary role in schizophrenia, Windrem and 
colleagues have adopted an ingenious experimental approach that represents one of the 
most creative and compelling uses of stem cell technology for disease modelling (Windrem el 
al., 2017). A number of years ago, while developing strategies for cell based therapies of 
myelin diseases, the laboratory of Steven Goldman (senior author in the paper by Windrem 
and colleagues) discovered that if human glial progenitor cells are grafted into the CNS of a 
new-born mouse, the human cells out-compete the endogenous mouse cells, resulting in a 
mouse developing with mouse neurons but human astrocytes, oligodendrocytes and glial 
progenitors (Windrem et al., 2014). Alert to the enormous potential of these mouse-human 
brain chimeras, the Goldman laboratory embarked on a series of studies that have 
transformed our understanding of glial cell biology, including the remarkable and previously 
under-recognised contribution that glia make to cognitive function (Han et al., 2013).  Now 
the laboratory has used iPSC technology to generate glial progenitors from skin samples taken 
from individuals with schizophrenia as well as from non-psychotic control individuals. When 
these schizophrenia-derived glial progenitors are transplanted into new-born mice, the mice 
develop with normal mouse neurons surrounded by ‘schizophrenic’ glia, albeit with 
decreased myelination and abnormally shaped astrocytes. Although challenging to assess, a 
number of mouse behavioural tests can be used to measure phenotypes that are analogous 
to the cognitive and behavioural changes expected in patients with schizophrenia. When 
subjected to these tests, the mice with ‘schizophrenic’ glia revealed signs of having 
‘schizophrenic’ behaviour. Thus, by an elegant experimental approach, the study provides 
unambiguous evidence that glia do indeed play a primary role in the disease pathogenesis, 
and that not all of the previously reported glial changes associated with the disease are 
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secondary consequences of primary neuronal pathology. This is not to say that there is not a 
primary neuronal component (which there almost certainly is), although a different approach 
is required to separate the neuronal from the glial component since the chimeric CNS model 
in which the species origin of the neurons and glia is reversed is not technically feasible.  
 
While representing a significant step forward in our understanding of the cellular basis of 
schizophrenia, many intriguing questions still remain to be answered. For example, the 
present study does not distinguish between the relative contributions made between 
astrocytes, oligodendrocytes or indeed their progenitors. There is also a wealth of data that 
has been generated in the study comparing gene expression patterns of schizophrenic versus 
normal human glia. Separating signal from noise and identifying the key genes responsible for 
the disease phenotype will be a substantial task.  Nevertheless, this challenging task will be 
worth embarking on since it is likely to lead to new and profound mechanistic insights into 
this complex disease with implications for innovative approaches to diagnosis, prediction and 
treatment of schizophrenia in the future.  
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